Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Y-mAbs Therapeutics Stock Down 5.0 %
YMAB opened at $17.40 on Friday. The firm has a market capitalization of $760.62 million, a P/E ratio of -5.63 and a beta of 1.15. The stock's 50 day moving average price is $15.73 and its two-hundred day moving average price is $12.10. Y-mAbs Therapeutics has a 12-month low of $6.50 and a 12-month high of $34.60.
Y-mAbs Therapeutics (NASDAQ:YMAB - Get Rating) last released its earnings results on Monday, August 8th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.26). The business had revenue of $10.80 million during the quarter, compared to analyst estimates of $11.22 million. Y-mAbs Therapeutics had a negative net margin of 338.68% and a negative return on equity of 79.40%. The business's quarterly revenue was down 1.4% compared to the same quarter last year. During the same period last year, the business earned ($0.53) EPS. As a group, analysts anticipate that Y-mAbs Therapeutics will post -1.7 earnings per share for the current year.
Analysts Set New Price Targets
Several research analysts have weighed in on the company. HC Wainwright reaffirmed a "buy" rating and issued a $63.00 target price on shares of Y-mAbs Therapeutics in a research report on Friday, April 29th. Wedbush lowered their price objective on Y-mAbs Therapeutics from $28.00 to $21.00 and set an "outperform" rating on the stock in a report on Tuesday, May 10th. Finally, BMO Capital Markets started coverage on Y-mAbs Therapeutics in a report on Thursday, June 23rd. They set an "outperform" rating and a $27.00 price objective on the stock. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $30.83.